Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 8/20 | 0.39 |
| ▸ | AKT1 | P31749 | 7/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1086020 | 0.88 | CYP2C9 (0.44) | CYP2C9NTRK1CYP3A4 | |
| SCHEMBL2351339 | 0.84 | CYP2C9 (0.48) | CYP2C9NTRK1CYP3A4RPS6KB1SYK | |
| SCHEMBL3509976 | 0.84 | MAP2K1 (0.52) | CYP2C9NUDT1PARP1 | |
| SCHEMBL3703817 | 0.83 | CYP2C9 (0.48) | CYP2C9NTRK1CYP3A4RPS6KB1AKT1 | |
| SCHEMBL1093899 | 0.82 | CYP2C9 (0.41) | CYP2C9NTRK1CYP3A4 | |
| SCHEMBL27934700 | 0.82 | NTRK1 (0.49) | CYP2C9NTRK1CYP3A4RPS6KB1AKT1 | |
| SCHEMBL2357072 | 0.82 | CYP2C9 (0.49) | CYP2C9CYP3A4 | |
| SCHEMBL3506159 | 0.82 | BRAF (0.51) | CYP2C9NTRK1CYP3A4RPS6KB1SYK | |
| SCHEMBL3705466 | 0.82 | CYP3A4 (0.52) | CYP2C9NTRK1CYP3A4PARP1 | |
| SCHEMBL2883743 | 0.82 | CYP2C9 (0.46) | CYP2C9NTRK1CYP3A4RPS6KB1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2009143024-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | CYP2C9 2176/4885NTRK1 1554/4885CYP3A4 3611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.